Current Status of Uterine Leiomyosarcoma in the Tohoku Region: Results of the Tohoku Translational Center Development Network Survey.

about

Current Status of Uterine Leiomyosarcoma in the Tohoku Region: Results of the Tohoku Translational Center Development Network Survey.

Item

http://www.wikidata.org/entity/Q38758661

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Current Status of Uterine Leio ...... er Development Network Survey.

@en

type

Item

label

Current Status of Uterine Leio ...... er Development Network Survey.

@en

prefLabel

Current Status of Uterine Leio ...... er Development Network Survey.

@en

P1476

Current Status of Uterine Leio ...... er Development Network Survey.

@en

P2093

Fumiaki Takahashi

http://www.w3.org/2001/XMLSchema#string

Hidekazu Nishigori

http://www.w3.org/2001/XMLSchema#string

Hidekazu Yamada

http://www.w3.org/2001/XMLSchema#string

Hideki Tokunaga

http://www.w3.org/2001/XMLSchema#string

Hiroaki Shimokawa

http://www.w3.org/2001/XMLSchema#string

Hirokazu Sato

http://www.w3.org/2001/XMLSchema#string

Hiroki Yamamoto

http://www.w3.org/2001/XMLSchema#string

Kazuyo Sato

http://www.w3.org/2001/XMLSchema#string

Kosuke Yoshinaga

http://www.w3.org/2001/XMLSchema#string

Nobuo Yaegashi

http://www.w3.org/2001/XMLSchema#string

P2860

Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study.

Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial.

Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial.

Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial.

Adjuvant therapy for high-grade, uterus-limited leiomyosarcoma: results of a phase 2 trial (SARC 005).

Retrospective review of 208 patients with leiomyosarcoma of the uterus: prognostic indicators, surgical management, and adjuvant therapy.

Clinical outcomes of uterine sarcomas: results from 14 years worth of experience in the Kinki district in Japan (1990-2003).

Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial.

Uterine sarcomas in Norway. A histopathological and prognostic survey of a total population from 1970 to 2000 including 419 patients.

The influence of primary site on outcomes in leiomyosarcoma: a review of clinicopathologic differences between uterine and extrauterine disease.

P2888

s10147-017-1097-y

P304

541-547

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10147-017-1097-Y

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-02-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28188392

http://www.w3.org/2001/XMLSchema#string